Provided by Tiger Trade Technology Pte. Ltd.

Pfizer

27.54
-0.0150-0.05%
Volume:11.05M
Turnover:304.27M
Market Cap:156.56B
PE:36.24
High:27.69
Open:27.64
Low:27.41
Close:27.55
52wk High:29.21
52wk Low:23.58
Shares:5.69B
Float Shares:5.64B
Volume Ratio:0.48
T/O Rate:0.20%
Dividend:1.72
Dividend Rate:6.24%
EPS(TTM):0.7599
EPS(LYR):1.36
ROE:5.01%
ROA:5.78%
PB:1.84
PE(LYR):20.18

Loading ...

Did Targeted XFG COVID Shots Just Recenter Pfizer's (PFE) Post‑Pandemic Investment Narrative?

Simply Wall St.
·
Sep 01

NYSE Most Active Issues

Dow Jones
·
Sep 01

Pfizer Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Sep 01

Trump Administration Announces Drug Pricing Deals with CSL, Astellas and Others

Reuters
·
Sep 01

Pfizer Pivots: New Trials Target Obesity, Cancer, Autoimmune

TIPRANKS
·
Aug 29

Pfizer EVP Cecile Guegan Files Initial Beneficial Ownership Statement

Reuters
·
Aug 29

Pfizer Extends Tucatinib Access With New Continuation Study: What Investors Should Know

TIPRANKS
·
Aug 29

Pfizer Expands Autoimmune Pipeline With New Early-Stage Trial of PF-08154225

TIPRANKS
·
Aug 29

Pfizer Targets China’s Obesity Market With New Phase 3 Berobenatide Trial

TIPRANKS
·
Aug 29

NYSE Most Active Issues

Dow Jones
·
Aug 28

FDA Approves Seasonal Covid-19 Vaccines from Moderna, Pfizer, BioNTech

Dow Jones
·
Aug 28

Pfizer and BioNTech receive FDA approval for XFG-adapted COVID-19 vaccine

TIPRANKS
·
Aug 28

Pfizer, BioNTech Win FDA Approval for XFG-Adapted COVID-19 Vaccine in High-Risk US Adults

Reuters
·
Aug 28

Pfizer - Shipping of Xfg-Adapted Covid-19 Vaccine to Begin Immediately

THOMSON REUTERS
·
Aug 28

Pfizer - 2026-2027 Covid-19 Vaccine Formula Targets Xfg Variant Per FDA Guidance

THOMSON REUTERS
·
Aug 28

Pfizer’s Korean Vyndamax Study Update: What It Means for ATTR-CM Investors

TIPRANKS
·
Aug 28

China's Drug Regulator Accepts Novo Nordisk's Application for Oral Wegovy

Reuters
·
Aug 27

Pfizer Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Aug 26

Pfizer Stock (PFE) Is a Buy despite Declining Revenues

TIPRANKS
·
Aug 24

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Aug 24